Stock CORALAB6 CORAL LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Coral Laboratories Limited

Equities

CORALAB6

INE683E01017

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:52 2024-04-30 am EDT 		5-day change 1st Jan Change
378.7 INR -1.34% Intraday chart for Coral Laboratories Limited +3.65% -12.97%
Apr. 24 Coral Laboratories Limited Appoints Ruchi Pipara as Company Secretary, Compliance Officer and Key Managerial Personnel CI
Mar. 29 Coral Laboratories Limited Announces Change in Registered Office Address CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 2,125 1,130 350.1 1,151 912.1 817.8
Enterprise Value (EV) 1 2,125 1,115 398.1 1,191 729.8 517.7
P/E ratio 17.1 x 11.1 x 4.91 x 8.49 x 10.1 x 12.7 x
Yield 0.34% 0.63% - - - -
Capitalization / Revenue 2.34 x 1.24 x 0.5 x 1.19 x 1.21 x 1.05 x
EV / Revenue 2.34 x 1.22 x 0.56 x 1.23 x 0.97 x 0.66 x
EV / EBITDA 13.7 x 8.85 x 6.98 x 7.33 x 8.51 x 12.2 x
EV / FCF 32.9 x -17.9 x -4.65 x -62.2 x -107 x 7.71 x
FCF Yield 3.04% -5.6% -21.5% -1.61% -0.93% 13%
Price to Book 1.83 x 0.99 x 0.3 x 0.84 x 0.58 x 0.53 x
Nbr of stocks (in thousands) 3,573 3,573 3,573 3,573 3,573 3,573
Reference price 2 594.8 316.3 98.00 322.2 255.3 228.9
Announcement Date 9/3/18 9/5/19 8/20/20 9/1/21 9/6/22 7/18/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 907.4 910.8 705.8 965.7 756.1 781.2
EBITDA 1 154.6 125.9 57 162.5 85.74 42.45
EBIT 1 139.2 107.1 37.12 142.8 65.97 20.73
Operating Margin 15.34% 11.76% 5.26% 14.79% 8.72% 2.65%
Earnings before Tax (EBT) 1 180.5 155.1 91.17 176.1 118.6 82.26
Net income 1 124.5 102.2 71.3 135.5 90.46 64.45
Net margin 13.72% 11.22% 10.1% 14.04% 11.96% 8.25%
EPS 2 34.84 28.60 19.96 37.94 25.32 18.04
Free Cash Flow 1 64.67 -62.38 -85.59 -19.15 -6.809 67.1
FCF margin 7.13% -6.85% -12.13% -1.98% -0.9% 8.59%
FCF Conversion (EBITDA) 41.83% - - - - 158.08%
FCF Conversion (Net income) 51.96% - - - - 104.11%
Dividend per Share 2 2.000 2.000 - - - -
Announcement Date 9/3/18 9/5/19 8/20/20 9/1/21 9/6/22 7/18/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 48 39.3 - -
Net Cash position 1 0.66 15.3 - - 182 300
Leverage (Debt/EBITDA) - - 0.8422 x 0.2419 x - -
Free Cash Flow 1 64.7 -62.4 -85.6 -19.2 -6.81 67.1
ROE (net income / shareholders' equity) 11% 8.88% 6.22% 10.7% 6.18% 4.15%
ROA (Net income/ Total Assets) 6.41% 4.85% 1.66% 5.73% 2.31% 0.71%
Assets 1 1,941 2,106 4,303 2,367 3,921 9,061
Book Value Per Share 2 326.0 318.0 324.0 382.0 437.0 433.0
Cash Flow per Share 2 5.040 8.310 3.110 6.510 7.010 17.20
Capex 1 47.3 28.1 13.8 13.6 55.5 19.5
Capex / Sales 5.21% 3.09% 1.95% 1.41% 7.34% 2.49%
Announcement Date 9/3/18 9/5/19 8/20/20 9/1/21 9/6/22 7/18/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CORAL LABORATORIES LIMITED Stock Coral Laboratories Limited
-12.97% 16.21M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CORALAB6 Stock
  4. Financials Coral Laboratories Limited